$IMMU - On our trading list. Dropped due to a drug delay concern. At just $10 or less this is a steal. Today another analyst gives their opinion. We also posted a larger story about this Wednesday, Cowen have a good analysis of the situation.Immunomedics launch delay beyond 12 months unlikely, says H.C. WainwrightA third party yesterday disclosed that Immunomedics received a Form 483 associated with the recently-completed FDA pre-approval inspection at the company's Morris Plains, NJ facility, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. Immunomedics has stated that the observations are largely related to compliance with current Good Manufacturing Practices and standard operating procedures, adds the analyst. Importantly, according Selvaraju, there were no citations for data integrity breaches. The analyst believes "there is now a small but not insignificant risk" that sacituzumab would not receive timely approval. However, a delayed market entry could permit a more normalized launch, says Selvaraju, who reiterates a Buy rating on Immunomedics with a $31 price target. He believes a delay beyond 12 months appears unlikely. $IMMU, Immunomedics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page